

Table S2 Patient Disposition – Randomized Population

Category	Placebo (N = 71) n (%)	MSDC-0160 50 mg (N = 72) n (%)	MSDC-0160 100 mg (N = 71) n (%)	MSDC-0160 150 mg (N = 71) n (%)	Pioglitazone 45 mg (N = 71) n (%)	Total (N = 356) n (%)
Randomized	71 (100.0)	72 (100.0)	71 (100.0)	71 (100.0)	71 (100.0)	356 (100.0)
Completed	56 (78.9)	59 (81.9)	62 (87.3)	56 (78.9)	64 (90.1)	297 (83.4)
Discontinued	15 (21.1)	13 (18.1)	9 (12.7)	15 (21.1)	7 (9.9)	59 (16.6)
Withdrawal by patient	4 (5.6)	5 (6.9)	3 (4.2)	4 (5.6)	0 (0.0)	16 (4.5)
Lost to follow-up	4 (5.6)	2 (2.8)	2 (2.8)	4 (5.6)	2 (2.8)	14 (3.9)
Required a prohibited medication	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Non-compliance with protocol	2 (2.8)	4 (5.6)	0 (0.0)	3 (4.2)	1 (1.4)	10 (2.8)
Investigator judgment	0 (0.0)	1 (1.4)	0 (0.0)	1 (1.4)	0 (0.0)	2 (0.6)
Protocol-defined hyperglycemia	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Adverse event	0 (0.0)	1 (1.4)	1 (1.4)	1 (1.4)	0 (0.0)	3 (0.8)
Other	4 (5.6)	0 (0.0)	2 (2.8)	2 (2.8)	4 (5.6)	12 (3.4)
ITT Population	66 (93.0)	69 (95.8)	66 (93.0)	69 (97.2)	67 (94.4)	337 (94.7)
Per-Protocol Population	56 (78.9)	48 (66.7)	52 (73.2)	47 (66.2)	55 (77.5)	258 (72.5)
Safety Population	71 (100.0)	71 (98.6)	71 (100.0)	70 (98.6)	71 (100.0)	354 (99.4)